04:39 , Jan 17, 2015 |  BC Extra  |  Top Story

Roche buys neuromuscular play Trophos

Roche (SIX:ROG; OTCQX:RHHBY) acquired neuromuscular disease play Trophos S.A. (Marseille, France) for EUR 120 million ($141.8 million) in upfront cash. Trophos shareholders are eligible for up to EUR 350 million ($413.6 million) in milestones. Last...
07:00 , May 29, 2001 |  BioCentury  |  Finance

France rising

French biotech is bucking the chilled markets. Indeed, counting this week's announcement of a E 35 million ($30.8 million) pre-IPO financing by neurological play Neurotech, five French biotech deals account for 26% of European company...
08:00 , Dec 7, 1998 |  BC Week In Review  |  Company News

Transgene, Association Francaise Contre Les Myopathies deal

The partners renewed until June 30, 2001 their agreement to develop gene therapy treatments for neuromuscular diseases, with a focus on Duchenne's Muscular Dystrophy (DMD). AFM will provide $14.7 million for the research project and...
08:00 , Dec 9, 1996 |  BC Week In Review  |  Company News

Oncogene, Association Francaise Contre Les Myopathies deal

The association will provide $700,000 to ONCS to support continuation of a discovery research program for Duchenne muscular dystrophy (DMD). The program is being conducted in collaboration with Cold Spring Harbor Laboratory and the University...